Indatuximab Ravtansine
- Product NameIndatuximab Ravtansine
- CAS1238517-16-2
- CBNumberCB28080846
- MW0
- MOL FileMol file
Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Indatuximab Ravtansine Chemical Properties,Usage,Production
Uses
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1].in vivo
Indatuximab ravtansine (5.3-21.2 mg/kg; i.v.; once) inhibits multiple myeloma tumour growth in vivo and improves host survival[1].
| Animal Model: | SCID mice inoculated with MOLP-8 multiple myeloma xenografts[1] |
| Dosage: | 5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg |
| Administration: | i.v.; once |
| Result: | Inhibited multiple myeloma tumour growth in vivo and improved host survival. |
References
[1] Kurt Schnfeld, et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10(1):13. DOI:10.1186/s13045-016-0380-0Indatuximab Ravtansine Suppliers
Global(16)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 027-65317797 15926423062 | 422450190@qq.com | 10300 | 58 | ||
| 177-54423994 17754423994 | 2853530910@QQ.com | 7999 | 62 | ||
| 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | 7353 | 58 | ||
| 15111215862 18229892877 | 3062105966@qq.com | 5580 | 58 | ||
| 027-65279366 18108604356 | products@biolabreagent.com | 9864 | 58 | ||
| 17316404525 17316404525 | 209533805@qq.com | 9790 | 58 | ||
| 021-65675885 18964387627 | customer_service@efebio.com | 11963 | 58 | ||
| 027-87008169 17762441161 | info@atagenix.com | 9997 | 58 | ||
| 400-821-0310 15002144251 | xuexiang.shao@tsbiochem.com | 29128 | 58 | ||
| 18007167883 18007167883 | Service@mabnus.com | 921 | 58 |